Stiripentol
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Stiripentol: From Dravet Syndrome to Restless Legs Syndrome
One-Sentence Summary
Stiripentol is an antiepileptic drug used as adjunctive therapy for Dravet syndrome (severe myoclonic epilepsy of infancy); this indication is derived from literature contained in the Evidence Pack, as official label data (original indication, MOA) is currently a documented data gap. The TxGNN model predicts it may also be effective for Restless Legs Syndrome, but this is currently the top-ranked prediction by score alone — it is supported by no clinical trials and no published literature.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Dravet syndrome (severe myoclonic epilepsy of infancy), adjunctive therapy (sourced from Evidence Pack literature context; official label text unavailable — see Data Gaps) |
| Predicted New Indication | Restless Legs Syndrome |
| TxGNN Prediction Score | 98.76% |
| Evidence Level | L5 |
| EU Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed structured mechanism-of-action data is not available in DrugBank for Stiripentol (data gap, DG002). Based on the literature referenced elsewhere in this Evidence Pack, Stiripentol acts as a GABAergic enhancer with additional CYP450-inhibitory properties, and is used as adjunctive antiepileptic therapy in Dravet syndrome — a severe, treatment-resistant childhood epileptic encephalopathy.
Restless Legs Syndrome, however, is primarily associated with dopaminergic pathway dysfunction and iron metabolism abnormalities — a pathophysiology that does not mechanistically overlap with GABAergic anticonvulsant activity. The Evidence Pack’s own mechanistic assessment for this candidate explicitly states that the link between Stiripentol’s mode of action and restless legs syndrome is weak, with no biological rationale beyond general neuro-modulatory activity.
This prediction currently reflects the model’s top-scoring output by TxGNN rank alone, not corroborating clinical or literature evidence. It should be treated as a low-confidence signal warranting no near-term action, rather than a validated repurposing hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
EU Market Information
No EU marketing authorizations are currently recorded for Stiripentol in this Evidence Pack (market status: not marketed; 0 authorizations).
Safety Considerations
Please refer to the SmPC for safety information.
(Note: TFDA/EMA label warnings, contraindications, and drug-drug interaction data are currently a documented data gap of Blocking severity — DG001 — which prevents progression to the S1 safety-screening stage for this candidate.)
Conclusion and Next Steps
Decision: Hold
Rationale: Although Stiripentol receives the highest TxGNN prediction score among the candidate indications in this Evidence Pack, the mechanistic rationale is weak (GABAergic anticonvulsant activity vs. dopaminergic/iron-metabolism-driven pathophysiology of restless legs syndrome), and there is currently zero clinical trial or literature evidence to support this specific repurposing hypothesis. The evidence level is L5 (model prediction only).
To proceed, the following is needed:
- Structured MOA data for Stiripentol (DG002, High severity)
- TFDA/EMA label warnings and contraindications to unblock S1 safety screening (DG001, Blocking severity)
- Preclinical or mechanistic studies specifically bridging GABAergic modulation to restless legs syndrome pathophysiology
- Any emerging clinical case reports or trials directly studying Stiripentol in restless legs syndrome before this candidate can be re-scored
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.